Silo Pharma (NASDAQ:SILO – Get Free Report) released its earnings results on Friday. The company reported ($0.21) earnings per share for the quarter, Zacks reports. Silo Pharma had a negative net margin of 6,726.39% and a negative return on equity of 81.75%.
Silo Pharma Price Performance
Shares of NASDAQ SILO traded down $0.07 during trading hours on Friday, reaching $1.84. The stock had a trading volume of 48,855 shares, compared to its average volume of 168,715. The business’s fifty day moving average is $1.57 and its two-hundred day moving average is $4.37. The company has a market cap of $2.93 million, a price-to-earnings ratio of -0.42 and a beta of 0.81. Silo Pharma has a twelve month low of $1.10 and a twelve month high of $10.43.
Wall Street Analyst Weigh In
Separately, Weiss Ratings lowered Silo Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has an average rating of “Sell”.
Read Our Latest Report on SILO
About Silo Pharma
Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on developing therapeutics that combine traditional pharmaceutical approaches with psychedelic research. The company’s programs are intended to address conditions involving pain, inflammation, neurological disorders, and mental health. Silo Pharma’s pipeline has included SP-26, an investigational ketamine-based implant designed to provide sustained drug delivery and being explored for conditions such as fibromyalgia. Its research portfolio has also included intranasal formulations and other therapeutics targeting disorders such as post-traumatic stress disorder and Alzheimer’s disease.
Featured Stories
- Five stocks we like better than Silo Pharma
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Silo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
